Prognostic value of high FoxC2 expression in resectable non-small cell lung cancer, alone or in combination with E-cadherin expression

Table 1 Correlations between staining of Foxc2, E-cadherin and clinicophathologic characteristics in 309 NSCLC patients

Variables	Foxc2-L	Foxc2-H	p	E-cadherin-I	E-cadherin-P	p
Variables	n = 227	n = 82	p	n = 127	n = 182	p
Age
≤ 65	89	26	0.062	45	70	0.551
> 65	138	56		82	112
Sex
Male	154	55	0.891	90	119	0.329
Female	73	27		37	63
Tobacco use
No	117	35	0.047	59	93	0.223
Yes	110	47		68	89
Pathological type
Adenocarcinoma	131	58	0.008^b	77	112	0.653^b
Squamous cell carcinoma	76	13		40	49
Other^a	20	11		10	21
TNM stage
I	45	17	0.679	22	40	0.432
II–III	182	65		105	142
pT status
T1	57	18	0.549	33	42	0.516
T2-4	170	64		94	140
pN status
N0	79	12	< 0.001	30	61	0.041
N1-2	148	70		97	121
Pleural involvement
No	181	68	0.372	98	151	0.245
Yes	46	14		29	31
Differentiation
Well/moderate	85	33	0.606	45	73	0.338
Poor	142	49		82	109
Vascular invasion
No	200	71	0.617	109	162	0.568
Yes	27	11		18	20

FoxC2-H high expression of FoxC2; FoxC2-L low expression of FoxC2
E-cadherin-I impaired expression of E-cadherin; E-cadherin-P preserved expression of E-cadherin
^a Other including adenosquamous carcinoma, mucoepidermoid carcinoma, carcinosarcoma, large-cell carcinoma, and atypical carcinoid
^b p value was analyzed by Adenocarcinoma vs. non- Adenocarcinoma using the chi-square test

ISSN: 1471-2407